Ultragenyx Pharmaceutical Inc. received accelerated FDA approval for GENGLYCOS, its first gene therapy targeting GSDIa. This milestone marks a significant advancement for the company and the gene therapy sector.
Ultragenyx Secures FDA Accelerated Approval for Gene Therapy GENGLYCOS
|1 min read
biotechnologygene-therapyFDA-approvalpharmaceuticalsUltragenyx
